Obesity

Latest News

Tirzepatide | Image Credit: © luchschenF-stock.adobe.com
Tirzepatide Surges, Overtakes Older Drugs in Diabetes, Obesity Care

April 14th 2025

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Additional research, argued the researchers, should examine the impact of more accessibility to nutritious foods on binge eating. | Image Credit: dizain - stock.adobe.com
Identifying Binge Eating Triggers Among Adults With Food Insecurity

April 12th 2025

Based on the model, over 3 million MACE were projected over the following 10 years, approximately 496,000 of which could be prevented with the use of semaglutide. | Image credit: peter hansen - stock.adobe.com
Semaglutide Use Could Prevent Up to 2 Million MACE in 10 Years, Model Suggests

April 9th 2025

Semaglutide. | Image Credit: K KStock - stock.adobe.com
Tirzepatide and Semaglutide Improve Weight Loss, Cardiovascular Conditions, but Deemed Too Expensive

March 14th 2025

Wei-Li Shao
Contributor: How Can the US Health Care System Affordably and Fairly Expand GLP-1 Access for the Millions of People Who Need it?

March 5th 2025

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo